Ambrx Biopharma Debt to Equity Ratio 2020-2022 | AMAM
Current and historical debt to equity ratio values for Ambrx Biopharma (AMAM) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Ambrx Biopharma debt/equity for the three months ending June 30, 2022 was 0.00.
| Ambrx Biopharma Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-06-30 |
$0.04B |
$0.14B |
0.28 |
| 2021-12-31 |
$0.04B |
$0.19B |
0.21 |
| 2021-06-30 |
$0.02B |
$0.19B |
0.11 |
| 2020-12-31 |
$0.02B |
$0.11B |
0.18 |
| 2019-12-31 |
$0.03B |
$0.03B |
0.85 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.335B |
$0.007B |
|
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
|
